Abcam has been such an amazing performer over the last couple of years.  The chart is phenomenal, and today spiked another 5%.  As far as I can see, it's getting pretty fully valued at 25X earnings, and the directors have been offloading enormous emounts over the last year - one founder (Cleeveley) sold £16m of stock on the 16th September.

But it seems to be blessed by the market and meet no resistance.  It's breaking out again 33% above it's 200 day moving average. 

Admittedly it's a great company with a really simple model as an antibody repository/catalog - it's from cambridge university research dept origins... and was snubbed by VCs - great stuff.

Anyone have any ideas? Is this just set to defy gravity and head to a p/e of 40x +++ ?

Unlock the rest of this Article in 15 seconds

or Unlock with your email